Доктор Вадим Викторович Гущин. Место работы: Институт Онкологической Помощи Мерси, Балтимор, Мериленд:

Доктор Вадим Викторович Гущин.
Место работы:
Институт Онкологической Помощи Мерси, Балтимор, Мериленд:
Хирург-онколог, директор гастроинтестинальной онкологической хирургии,
директор программы специализации по хирургической онкологии.
2006 – настоящее время.
Опыт работы по организации новых программ:
Организация частного онкологического центра. Луганск, Украина. 2012.
Организация центра циторедуктивной хирургии и внутриперитонеальной
химиотерапии в Иркутском Областном Онкологическом Диспансере, Иркутск,
Россия. 2011.
Организация центра циторедуктивной хирургии и внутриперитонеальной
химиотерапии в госпитале Вильнюсского Университета, Литва. 2011
Организация центра онкологической хирургии с использованием операционного
робота да Винчи в госпитале Мерси, Балтимор, США. 2011
Специализация:
Специализация по хирургической онкологии
Институт Онкологии имени Розвелла Парка
2004-2006
Специализация по хирургии поджелудочной железы
Кафедра Хирургии Гейдельбергского Университета, Германия
2008
Специализация по хирургии рака желудка
Национальный Институт Рака, Токио, Япония
2004
Хирургическое обучение:
Резидентура по общей хирургии (2-5 года обучения)
Вашингтонский Госпитальный Центр
Вашингтон, округ Колумбия
1999 – 2004
Резидентура по общей хирургии (1-ый год обучения)
Госпиталь Университета Пенсильвании
Филадельфия, Пенсильвания
1998 – 1999
Ординатура по хирургии
Кафедра Общей Хирургии РГМУ
Москва
1993 – 1995
Высшее образование:
Лечебный факультет Российского Государственного Медицинского Университета
Москва. Диплом с отличием.
1987- 1993
Приглашённые лекции:
1. XVI Российский Онкологический Конгресс, ноябрь 2012, Москва.
«Хирургическое лечение перитонеального карциноматоза рака толстой
кишки.»
2. VIII Всероссийский Съезд Онкологов, сентябрь 2013, Санкт-Петербург.
«Циторедуктивная хирургия: от аппендикса до толстой кишки».
Семинары (включая веб-семинары):
1. Российский онкологический научный центр им. Н. Н. Блохина. Заведующий
кафедрой онкологии Факультета усовершенствования врачей Хайленко
Виктор Алексеевич. 2013.
2. Тамбовский областной онкологический диспансер. Главный врач:
Милованов Владимир Васильевич. 2013-2014.
3. Лечебно-реабилитационный центр, Москва. Заведующий отделением
хирургической онкологии: Лядов Владимир Константинович. 2013.
Публикации:
1. Gushchin V, Stegalkina S, Alam HB, Kirkpatrick JR, Rhee PM, Koustova E.
Cytokine expression profiling in human leukocytes after exposure to hypertonic and
isotonic fluids. Journal of Trauma-Injury Infection & Critical Care 52(5):867-71, 2002
2. Koustova E, Stanton K, Gushchin V, Alam HB, Stegalkina S, Rhee PM. Effects of
lactated Ringer’s solutions on human leukocytes. Journal of Trauma-Injury Infection &
Critical Care 52(5):872-8, 2002
3. Alam HB, Bowyer MW, Koustova E, Gushchin V, Anderson D, Stanton K,
Kreishman P,
Cryer CM, Hancock T, Rhee P. Learning and memory is preserved after induced
asanguineous hyperkalemic hypothermic arrest in a swine model of traumatic
exsanguination. Surgery 132(2):278-88, 2002
4. Brackman MR, Gushchin V, Smith L, Demory M, Kirkpatrick JR, Stahl T. Acute
lower gastroenteric bleeding retrospective analysis (the ALGEBRA studay): an analysis
of the triage, management and outcomes of patients with acute lower gastrointestinal
bleeding. American Surgeon 69(2):145-9, 2003
5. Gushchin V, Alam HB, Kirkpatrick JR, Rhee PM, Koustova E. Transcription
Profiling in Leukocytes Exposed to Hypertonic Resuscitation Fluids. Journal of the
American College of Surgeons 197:426-432, 2003
6. Gushchin V, Ross A, Miller D, Nieroda C, Kalesan B, Studeman K, Kostuik P, Sardi
A. Complete Cytoreduction Offers Long-term Survival in Patients with Peritoneal
Carcinomatosis from Appendiceal Tumors of Unfavorable Histology. JACS. 2009 Sept;
2009(3): 308-312
7. Ross A, Sardi A, Nieroda C, Merriman B, Gushchin V. Clinical Utility Of Elevated
Tumor Markers In Patients With Disseminated Appendiceal Malignancies Treated By
Cytoreductive Surgery And HIPEC European Journal of Surgical Oncology 36 (2010) pp.
772-776
Презентации:
1. American Association for the Surgery of Trauma, 61 Annual Meeting. “Is Hypertonic
Saline Immunosuppressive? Genes Tell a Different Story.” Oral presentation. Seattle,
Washington, September 2001
2. 25th Annual Conference on Shock. “Resuscitation Fluids Activate Stress Genes in
Human Leukocytes.” Poster presentation. Big Sky, Montana, June 2002
3. The American College of Surgeons 88th Annual Clinical Congress. Oral presentation
at the Surgical Forum. “Transcription Profiling in Leukocytes Exposed to Hypertonic
Resuscitation Fluids in Vitro.” San Francisco, California, October 2002
4. The American College of Surgeons 31st Spring Meeting. Surgical Jeopardy Finalist.
New York, New York, April 2003
5. The 40th World Congress of the International Society of Surgery. “Analysis of the
triage, management and outcomes of patients with acute lower gastrointestinal bleeding.”
Oral presentation. Bangkok, Thailand, August 2003
6. The 6th World Congress on Trauma, Shock, Inflammation and Sepsis. “Resuscitative
Fluid-induced Human neutrophil Activation Correlates with Changes in Expression of the
Redox-sensitive Genes.” Oral poster presentation. Munich, Germany, March 2004
7. The Society of Surgical Oncology 58th Annual Cancer Symposium. “Prospective
Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Intraperitoneal
Chemotherapy to treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy.”
Oral presentation at the Plenary Session. Atlanta, Georgia, March 2005
8. The 2007 Gastrointestinal Cancer Symposium. “Cytoreductive surgery and
intraperitoneal hyperthermic chemoperfusion as part of a general surgical oncology
program.” Poster Presentation, Orlando, FL, January 2007
17. “Temporary mesenterico-caval shunt is a safe and effective technique of venous
resection during a Whipple procedure.” Presented at the 10th World Congress of the
International Hepato-Pancreato-Billary Association in Paris, France July 1-5, 2012
18. “Treatment of peritoneal carcinomatosis of colorectal origin with cytoreductive
surgery and HIPEC.” 16th Russian Oncological Congress, Moscow Russia, November
2012
19. B Gallagher, A Sardi, C Nieroda, H El-Halabi, V Gushchin. Incidental Papillary
Carcinoma in Patients Treated Surgically for Benign Thyroid Disease. Poster
Presentation at the Southeastern Surgical Congress 2013 Annual Scientific Meeting,
Jacksonville, Florida, February
9-12, 2013
20. Shankar S, Sittig M, Nieroda C, MacDonald R, Gushchin V, Sardi A. Extended
Survival in the Elderly Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal
Chemotherapy (CRS/HIPEC). Presented at Society of Surgical Oncology 66th Annual
Cancer Symposium Meeting in Washington DC, March 6-9, 2013.
21. Shankar S, Sardi A, Sittig M, Nieroda C, MacDonald R, Gushchin V. The Role of
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with
Primary Peritoneal Carcinoma (PPC) with Failed Conventional Treatment. Presented at
Society of Surgical Oncology 66th Annual Cancer Symposium Meeting in Washington
DC, March 6-9, 2013.
22. Sardi A, Gushchin V, Nieroda C, Sittig M, Shankar S, Francis J, MacDonald R,
Ledakis P. Melphalan: A Promising Agent in Patients Undergoing Cytoreductive
Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Presented at
Society of Surgical Oncology 66th Annual Cancer Symposium Meeting in Washington
DC, March 6-9, 2013.
Главы:
Vadim Gushchin, John Kane III, Michael Wong, William Kraybill. “Soft Tissue
Sarcoma” In “Multidisciplinary Treatment and Management of Cancer in the Elderly” 2 nd
edition.
Ed: Hyman B. Muss, Karen A. Johnson, Carrie P. Hunter
Taylor & Francis Group, LLC 2006
Armando Sardi, Hatem El-Halabi, Vadim Gushchin, Suven Shankar. Neoplasms of the
appendix. Hem/Onc Clinics Journal. September 2012
Абстракты:
1. Gushchin V, Stegalkina S, Alam HB, Rhee P, Koustova E. Is hypertonic saline really
immunosuppressive? Genes tell a different story. Journal of Trauma 51:211, 2001
2. Gushchin V, Alam HB, Kirkpatrick J, Rhee P, Koustova E. Transcriptional profiling
in leukocytes exposed to hypertonic resuscitation fluids in vitro. Journal of the American
College of Surgeons 195(supp):S85, 2002
3. Gushchin V, Alam HB, Kirkpatrick JR, Rhee P, Koustova E. Resuscitation fluids
activate stress genes in human leukocytes. Shock 17(supp):38, 2002
4. Gushchin V, Alderman R, Sugarbaker P. Prospective morbidity and mortality
analysis of 541 consecutive treatments with cytoreductive surgery and perioperative
intraperitoneal chemotherapy in patients with peritoneal carcinomatosis. Annals of
Surgical Oncology 12;2(supp):S26, 2005
5. Gushchin V, Ross A, Nieroda C, Kalesan B, Kostuik P, Holter D, Sardi A. Common
tumor markers predict extent of disease and success of cytoreductive surgery in patients
with appendiceal malignancies. J Clin Oncol 26: 2008, May 2008; 15527
6. Sardi A, Omohwo C, Nieroda C, Holter D, Athas N, Gushchin V. Bowel
Complications In Patients with Peritoneal Carcinomatosis of Appendiceal Origen Treated
with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of
Surgical Oncology. February 2010;17(1)165: 85-86
7. Thieme H, Gushchin V, Sardi A, Athas N. Peritoneal Carcinomatosis in the Geriatric
Patient: Outcomes with Cytoreductive Surgery and HIPEC. Annals of Surgical
Oncology. February 2010;17(1) 290: 123
8. El Halabi H, Gushchin V, Francis J, MacDonald R, Athas N, Sardi A. Lymph node
metastasis predicts survival in patients with high-grade appendix cancer. Ann Surg
Oncol. February 2011; 18(1) 154: 86
9. El Halabi H, Gushchin V, Francis J, MacDonald R, Sardi A. Patients with high-grade
Appendix cancer and extensive disease benefit from cytoreductive surgery and heated
Intraperitoneal chemotherapy. Ann Surg Oncol, February 2011; 18(1) 203: 101
10. El Halabi H, Gushchin V, Francis J, Nieroda C, Sardi A. The role of cytoreductive
surgery in patients with carcinomatosis from high-grade appendix cancer in the era of
modern systemic chemotherapy. J Clin Oncol 29: 2011 (suppl; abstr 4080)
11. A Sardi, V Gushchin, C Nieroda, M Sittig, S Shankar, J Francis, R MacDonald.
Repeated Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
(CRS/HIPEC) in
Patients with Peritoneal Carcinomatosis from Appendiceal Cancer. Accepted for paper
presentation at the 8th International Workshop on Peritoneal Surface Malignancy, Berlin,
Germany, October 30 – November 2, 2012
12. A Sardi, V Gushchin, C Nieroda, M Sittig, S Shankar, J Francis, R MacDonald, P
Ledakis.
Intraperitoneal Melphalan in Patients Undergoing Cytoredutive Surgery and
Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
International Workshop on Peritoneal Surface Malignancy, Berlin, Germany, October,
2012
13. B Gallagher, A Sardi, C Nieroda, H El-Halabi, V Gushchin. Incidental Papillary
Carcinoma in Patients Treated Surgically for Benign Thyroid Disease. Submitted for
presentation to the Southeastern Surgical Congress 2013 Annual Scientific Meeting,
Jacksonville, Florida, February 9-12, 2013
14. Shankar S, Sittig M, Nieroda C, MacDonald R, Gushchin V, Sardi A. Extended
Survival in the Elderly Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal
Chemotherapy (CRS/HIPEC). Proceedings of the Society of Surgical Oncology 66th
Annual Cancer Symposium: P210 (2013).
15. Shankar S, Sardi A, Sittig M, Nieroda C, MacDonald R, Gushchin V. The Role of
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with
Primary Peritoneal Carcinoma (PPC) with Failed Conventional Treatment. Proceedings
of the Society of Surgical Oncology 66th Annual Cancer Symposium: P213 (2013).
16. Sardi A, Gushchin V, Nieroda C, Sittig M, Shankar S, Francis J, MacDonald R,
Ledakis P. Melphalan: A Promising Agent in Patients Undergoing Cytoreductive
Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Proceedings of
the Society of Surgical Oncology 66th Annual Cancer Symposium: P232 (2013).